KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs.
Business Segments
The company operates through several segments, each of which plays a distinct role in its overall operations. The primary business segments are as follows:
Pharmaceutical segment
This segment encompasses the research, development, manufacturing, and sales of prescription drugs. This segment is focused on the development of innovative drugs i...
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs.
Business Segments
The company operates through several segments, each of which plays a distinct role in its overall operations. The primary business segments are as follows:
Pharmaceutical segment
This segment encompasses the research, development, manufacturing, and sales of prescription drugs. This segment is focused on the development of innovative drugs in the fields of respiratory medicine, urology, and otolaryngology. The company’s pharmaceutical products are designed to address a wide range of medical conditions, and its research activities. The pharmaceutical segment includes the entire process of drug development, from initial discovery to clinical trials, regulatory approval, and commercialization.
Consumer Healthcare segment
This segment is involved in the development and sales of consumer healthcare products. This segment includes over-the-counter (OTC) drugs, health supplements, and other products that support general health and wellness.
International segment
This segment is responsible for the development and marketing of its products in overseas markets. The company has established subsidiaries in the United States (Kyorin USA, Inc.) and Europe (Kyorin Europe GmbH) to facilitate its global operations.
Business Strategy
The company’s business strategy is centered on the development and commercialization of innovative pharmaceutical products that address unmet medical needs. The company’s strategic priorities include the identification of core therapeutic areas, the enhancement of its research and development capabilities, the expansion of its product portfolio, and the pursuit of global growth opportunities.
The company’s approach to drug development is based on a combination of in-house research and strategic alliances with domestic and international partners. The company actively seeks collaborations with other pharmaceutical companies, academic institutions, and research organizations to leverage external expertise and to accelerate the development of new drugs. The company’s strategy emphasizes the importance of open innovation and the integration of cutting-edge technologies in its research activities.
The company’s focus on core therapeutic areas, such as respiratory medicine, urology, and otolaryngology, enables it to concentrate its resources on areas where it has established expertise and where there is significant medical need. The company’s strategy involves the continuous evaluation of market trends and the identification of emerging opportunities for drug development. The company’s pipeline includes both original drugs and improved formulations of existing products.
The company’s global strategy is aimed at expanding its presence in key international markets and at increasing its competitiveness in the global pharmaceutical industry. The company’s subsidiaries in the United States and Europe play a vital role in its international operations, facilitating the registration, approval, and marketing of its products in those regions.
Products and Services
The company’s products and services encompass a wide range of pharmaceutical and healthcare offerings. The company’s primary products are prescription drugs, which are developed, manufactured, and marketed for the treatment of various medical conditions. The company’s product portfolio includes original drugs, generic drugs, and improved formulations of existing products.
The company’s core therapeutic areas are respiratory medicine, urology, and otolaryngology. In respiratory medicine, the company offers drugs for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. The company’s urology products include drugs for the treatment of urinary tract infections, benign prostatic hyperplasia, and other urological conditions. In otolaryngology, the company provides drugs for the treatment of ear, nose, and throat disorders.
In addition to prescription drugs, the company offers consumer healthcare products, including over-the-counter (OTC) drugs, health supplements, and other products that support general health and wellness.
The company’s services include the provision of information to healthcare professionals regarding the appropriate use of its products. The company’s sales representatives are responsible for promoting its products to medical institutions and for providing support to healthcare providers. The company’s customer support services include the handling of inquiries, complaints, and requests for information.
Geographical Markets
The company serves both domestic and international markets. In Japan, the company’s products are distributed to medical institutions, pharmacies, and retail stores. The company’s international operations include subsidiaries in the United States (Kyorin USA, Inc.) and Europe (Kyorin Europe GmbH), which are responsible for the development and marketing of its products in those regions.
Customers
The company’s customers include medical institutions, healthcare professionals, pharmacies, and retail stores. The company’s primary customer category is healthcare professionals, who prescribe its pharmaceutical products to patients. The company also serves medical institutions, such as hospitals and clinics, which purchase its products for use in patient care.
The company’s consumer healthcare products are marketed to the general public through pharmacies and retail stores. The company’s customer base includes individuals seeking effective solutions for common health issues.
The company’s sales division is responsible for managing relationships with customers and for providing support to healthcare providers. The company’s customer support services include the handling of inquiries, complaints, and requests for information. The company’s international subsidiaries serve customers in the United States and Europe, including medical institutions, healthcare professionals, and distributors.
Sales and Marketing
The company’s sales and marketing activities are conducted through a combination of direct sales, distribution partnerships, and promotional campaigns. The company’s sales representatives are responsible for promoting its products to healthcare professionals and for providing information regarding their appropriate use.
The company’s marketing division develops strategies to increase awareness of its products and to support their adoption by medical institutions. The company’s promotional activities include the organization of seminars, conferences, and educational programs for healthcare professionals.
The company’s distribution channels include direct sales to medical institutions, partnerships with wholesalers and distributors, and retail sales through pharmacies and stores. The company’s international subsidiaries manage the distribution of its products in overseas markets.
The company’s marketing activities are designed to provide accurate information to healthcare professionals and to promote the appropriate use of its products. The company’s sales division collaborates with its marketing division to ensure the effective promotion and distribution of its products.
Government Regulations
The company’s operations are conducted in compliance with the Pharmaceutical and Medical Device Act, the Good Manufacturing Practice (GMP) standards, and other relevant regulations.
History
KYORIN Pharmaceutical Co., Ltd. was founded in 1923. It was incorporated in 1958. The company was formerly known as KYORIN Holdings, Inc.
Das Analystenkursziel zeigt auf einen Blick die Mindest-, Höchst- und Durchschnittserwartung der Analysten.
